Is Raloxifene or Tamoxifen more effective on reducing the risk of developing invasive breast cancer and other disease outcomes?
- Vogel, V.G., 2006. Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA: The Journal of the American Medical Association 295, 2727–2741.
- 19,747 postmenopausal women of average age 58.5 years with increased 5-year breast cancer risk
Oral tamoxifen (20mg/d) or raloxifene (60mg/d) was taken over 5 years.
- There were 163 cases of invasive breast cancer in women assigned to tamoxifen and 168 in those assigned to raloxifene (incidence, 4.30 per 1000 vs 4.41 per 1000).
- There were fewer cases of noninvasive breast cancer in the tamoxifen group (57 cases) than in the raloxifene group (80 cases).
- There were 36 cases of uterine cancer with tamoxifen and 23 with raloxifene.
- No differences were found for other invasive cancer sites, for ischemic heart disease events, or for stroke.
- The number of osteoporotic fractures in the groups was similar. There were fewer cataracts and cataract surgeries in the women taking raloxifene.
- There was no difference in the total number of deaths (101 vs 96 for tamoxifen vs raloxifene) or in causes of death.
- Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer
- Potential conflict of interest associated with two of the authors who have both declared that they have worked for Eli Lilly & Company (who market Raloxifene).